1. Introduction {#s0005}
===============

The interest of scientific community to identify and characterize bioactive constituents from various plant extracts for suitable use in pharmaceutical industry or in composition of functional foods is significantly increasing. Today, it is generally accepted that nutrition plays an important role in the prevention of different chronic diseases and decreasing the risk factors by virtue of its functional ingredients. Among the broad category of plant-derived bioactive compounds, flavonoids are found to possess multiple health benefits. Therefore they are being considered as a medicinally important class of dietary molecules ([@b0625]). These plant-based secondary metabolites are known to represent a number of structurally diverse classes of polyphenols with potential pharmacological activities, including anticancer, anti-inflammatory, antioxidant, and anti-pathogenic properties ([@b0620], [@b0625]). Indeed, numerous *in vitro* and *in vivo* studies have reported the ability of flavonoids to interfere in different stages of carcinogenesis like migration, invasion, metastasis, and angiogenesis ([@b0625]). Moreover, epidemiological studies have shown that long-term and regular consumption of dietary items rich in flavonoids, such as fruits and vegetables, are associated with the lower risk of malignancy developments ([@b0035], [@b0405], [@b0715]). The daily intake of flavonoids among humans is still greatly variable, ranging from about twenty milligrams to virtually one gram ([@b0320]). Although, flavonoids are characterized by a common skeleton of diphenyl propane, they can be further subdivided into flavanols, flavonols, flavones, flavanones, isoflavones and anthocyanins based on the peculiarities in their chemical structures ([@b0035], [@b0405], [@b0650], [@b0715]).

Kaempferol (KMF), a well characterized natural flavonol, is present in 80% of plant-based foods, including broccoli, kale, cabbage, leek, tomato, beans, grapes, strawberries, apples, and tea ([@b0100], [@b0105], [@b0320], [@b0365], [@b0620]). It has been reported that KMF has potential to significantly modulate a variety of signaling pathways that are involved in many adverse clinico-pathological conditions ([@b0035], [@b0100], [@b0320], [@b0365], [@b0620]). In contrast to the standard chemotherapeutic drugs utilized in cancer treatment at present, KMF showed minimal side effects evidenced in the different experiments along with its effective synergistic ability in combination with various synthetic cytotoxic drugs ([@b0100], [@b0105], [@b0365], [@b0620]). However, essential efforts are still needed to uncover its unexplored health benefits. This review highlights the multiple molecular targets of KMF that are involved in a variety of cellular signaling pathways. In addition to this, the review also discusses synergistic studies of KMF with other known therapeutic drugs along with its pharmacokinetics and epidemiological findings.

2. Chemistry and source of kaempferol {#s0010}
=====================================

Kaempferol (3,5,7-trihydroxy-2-(4-hydroxyphenyl)-4*H*-chromen-4-one) was initially discovered in *Camellia sinensis* (tea tree) and is abundant in different genera of plants such as *Capparis spinosa* (Capers) *and Crocus sativus* (Saffron) ([@b0080], [@b0170], [@b0540]). [Table 1](#t0005){ref-type="table"} summarizes the list of all sort of natural sources of KMF (see [Fig. 1](#f0005){ref-type="fig"} ).Table 1An overview about the sources of KMF and its derivatives.S. noDerivativesPlant sources1.Kaempferol*Macrothelypteris torresiana* Ching var. *calvata* Holtt.*Notholaena standleyi* Maxon*Osmunda cinnamomea* L. var. *asiatica* Fern.*Pityrogramma triangularis*Maxon var. *triangularis*2.Kaempferol 4′-methyl ether*Asplenium diplazisorum* Hieron*Notholaena standleyi* Maxon*Pityrogramma triangularis*3.Kaempferol 7-methyl ether*Cheilanthes albomarginata* Clarke4.Kaempferol 3-methyl ether*Notholaena candida*Var. *candidaN. candida* Hook. Var*Copelandii TryonN. standleyi* Maxon*Pityrogramma triangularis*Maxon var. *triangularis*5.Kaempferol 5-methyl ether*Pityrogramma triangularis*Maxon var. *triangularis*6.Kaempferol 3-sulphate*Adiantum capillus-veneris* L.7.Kaempferol 7,4′-dimethyl ether*Cheilanthes farinosa* KIfC. *grisea* Blanf.C. *kauifussii* Kze.8.Kaempferol 3,4′-dimethyl ether*Notholaena nivea* Desv.*N. standleyi* Maxon*Pityrogramma triangularis*Maxon var. *triangularis*9.Kaempferol 3,7-dimethyl ether*Cheilanthes albomarginata* ClarkeC. *farinosa* KifC. *kaulfussii* Kze. jC. *longissima*C. *rufa* D. Don*Notholaena bryopoda* Maxon*N. cali{ornica* D.C. Eaton (white farina)*N. limitanea* var. *mexicana* Broun10.Kaempferol 3,7,4′-trimethyl ether*Cheilanthes farinosa* Kif.C. *grisea* Blanf.C. *kaulfussii* KzeC. *longissimaNotholaena hryopoda* Maxon*N. Iimitanea* var. *mexicana* Broun*Pityrogramma triangularis*Maxon var. *triangularis*11.Kaempferol 3-O-β-D-glucoside*Acrophorus nodosus* Pro*Adiantum aethiopicum* L.*A. capillus-veneris* L.*A. cuneatum* Langsd.*A. monochlamys* D.C. Eaton*Alsophila spinulosaChristella acuminata* Lev.C. *parasitica* Lev.*Cyathea contaminans* Copel.C. *hancockii* Copel.C. *leichhardtiana* Copel.C. *mertensiana* Copel.C. *podophylla* Hook.*Cystopteris fragilis* Bernh*Davallia divaricata* Bl.*Dennstaedtia scabra* Moore*D. wilfordii* Christ*Hypodematiurn crenatum* Kuhn*H. fauriei* Tagawa*Onoclea sensibilis* L. var. *interrupta* Maxim.*Osumunda cinnamomea* L. var *asiatica* Fern.*Peranema cyatheoides* Don*Phymatodes scolopendria* Ching *Plagiogyria matsumureana* Makino12.Kaempferol 3-O-α-D-glucoside*Athyriumfilix-foemina* Roth13.Kaempferol 3-(6-malonyl)-D-glucoside*Ceterach officinarum* DC14.Kaempferol 3-O-(3-O-sulfo)-β-D-glucoside*Cystopteris fragilis* Bernh.15.Kaempferol 3-O-(6-O-sulfo)-β-D-glucoside*Cystopteris fragilis* Bernh.16.Kaempferol 3-O-(6-O-sulfo)-α-D-glucoside*Athyriumfilix-foemina* Roth17.Kaempferol 3-O-β-D-alloside*Acystopteris japonica* Nakai*Osmunda cinnamomea* L. var. *asiatica* Fern*Wagneriopteris nipponica* Loeve et Loeve18.Kaempferol 3-O-β-D-galactoside*Adiantum malesianum* Gatak*A. monochlamys* D. C. Eaton*Cyathea hancockii* CopelC. *podophylla* Hook19.Kaempferol 3-O-α-D-galactoside*Adiantum malesianum* Gatak20.Kaempferol 3-(6-malonyl)-D-galactoside*Ceterach officinarum* DC21.Kaempferol 3-glucuronide*Adiantum capillus-veneris* L.*A. cuneatum* Langsd.22.Kaempferol 3-O-α-L-rhamnoside*Alsophila spinulosa* Tryon*Cyathea contaminans* CopelC. *hancockii* Copel.C. leichhardtiana CopelC. *mertensiana* Copel.C. *podophylla* Hook.*Glaphyropteridopsis erubescens* Ching*Pteris ryukyuensis* Tagawa23.Kaempferol 7-(6-succinyl)-glucoside*Cyathea contaminans* Copel.24.Kaempferol 7-arabinoside*Alsophila spinulosa* Tryon*Cyathea hancockii* Copel.C. *leichhardtiana* Copel.C. *mertensiana* CopelC. *podophylla* Hook.25.Kaempferol 3,7-diglucoside*Asplenium bulbiferum* Forst.*A. platyneuron* Oakes26.Kaempferol 3-glucoside-7-galactoside*Asplenium bulbiferum* Forst.27.Kaempferol 3-O-rhamnoside-7-O-glucoside*Asplenium bulbiferum* Forst28.Kaempferol 3,7-di-O-α-L-rhamnoside*Asplenium trichomanes* L.*Onychium contiguum* Hope*Pteris podophylla* Sw.29.Kaempferol 3-O-rhamnoside-7-O-arabinoside*Asplenium trichomanes* L30.Kaempferol 3-O-α-L-arabinoside-7-O-α-L-rhamnoside*Woodsia polystichoides* Eaton31.Kaempferol 3-O-arabinoside-7-O-rhamnoside*Asplenium trichomanes* L*.Polyposdium vulgare* L*.*32.Kaempferol 3-O-(3-Oacetyl)-α-L-arabinoside-7-O-α-L-rhamnoside*Woodsia polystichoides* Eaton33.Kaempferol 3,4′-diglucoside*Cystopteris fragilis* Bemh.34.Kaempferol 3-sophoroside*Alsophila spinulosa* Tryon*Cyathea contaminans* CopelC. *leichhardtiana* CopelC. *mertensiana* Copel35.Kaempferol 3-O-β-gentiobioside*Asplenium fontanum* Bernh. var. *obovatum*36.Kaempferol *3*--*0-(6′*-sulfo) gentiobioside*Asplenium fontanum* Bernh. var. *obovatum*37.Kaempferol 3-O-β-rutinoside*Adiantum capillus-veneris* L.*Cyathea hancockii* Copel.C. *podophylla* Hook*Macrothelypteris torresiana* Ching var *calvata* Holtt.*Paesia anfractuosa* C. Chr.*Pteris excelsa* Gaud.*Thelypteris palustris* Schott38.Kaempferol 3-O-sulforutinoside*Adiantum capillus-veneris* L*.*39.Kaempferol 3-O-\[2-O-(6-O-caffeoyl-β-D-glucosyl)\]-β-D-galactoside*Brainea insignis* J. Sm.40.Kaempferol 3-glucosylarabinoside*Phegopteris polypodioides* Fee41.Kaempferol *3-O-(4* or 5-rhamnosyl)-sarabinoside*Polypodium vulgare* L.42.Kaempferol7-rhamnosylglucoside*Alsophila spinulosa* Tryon*Cyathea contaminans* CopelC. *leichhardtiana* CopelC. *mertensiana* Copel43.Kaempferol 3-O-\[3-O-(4-O-caffeoyl-β-D-glucosyl)\]-β-D-glucoside-7-O-rhamnoside*Phyllitis scolopendrium* Newm.44.Kaempferol 3-O-sophorotrioside-7-O-glucoside*Asplenium septentrionale* Hoffm.45.Kaempferide 3,7-diglucoside*Asplenium bulbiferum* Forst46.Kaempferide 3-O-glucoside-7-O-rhamnoside*Asplenium bulbiferum* Forst.47.Kaempferide 3-rhamnoside-7-glucoside*Asplenium bulbiferum* Forst.48.Kaempferol 3--0-gentiobioside-7,4′-diglucoside*Asplenium nidus* L.49.Kaempferol 3,4′-dimethyl ether 7-glucoside*Asplenium platyneuron* Oakes50Kaempherol 3,5-dimethyl ether 4′-O-β-D-glucoside*Colysis wrightii* Ching[^1][^2]Fig. 1This figure illustrates the chemical nature and physical characteristics of KMF. (a) The flavonoid diphenyl propane skeleton; (b) Chemical structure of KMF; (c) Physical properties of KMF.

2.1. Biosynthetic preview {#s0015}
-------------------------

The biosynthetic approach of KMF is known to involve the condensation of cinnamoyl-CoA (1) and malonyl-CoA (2) in the presence of chalcone synthase, a catalytic enzyme, which results in the formation of naringenin-chalcone (3). Chalcone has been considered as the most widely studied precursor for a variety of flavanol synthesis. Further, chalcone isomerase mediates isomerisation reactions and leads to the formation of naringenin (flavanone) (4). In the next step, the hydroxylation is known to occur at C3 position of naringenin by flavanone 3-dioxygenase which leads to the synthesis of dihydrokaempferol (5). In the last step, flavonol synthase mediated exordium of a double bond at the C2--C3 position occurs in the dihydrokaempferol skeleton which results in the formation of KMF ([@b0170]) ([Fig. 2](#f0010){ref-type="fig"} ). Naturally, KMF is also known to exist in conjugate forms with different sugar molecules such as rutinose, rhamnose, glucose and galactose that cause the formation of glycosidic combinations of KMF, such as astragalin (kaempferol-3-O-glucoside), kaempferol-3-beta-D-galactoside, kaempferol-3-rutinoside. Besides these, other derivatives, such as kaempferol methyl ether, kaempferol dimethyl ether, kaempferol trimethyl ether and kaempferol sulphate have also been noted ([@b0080], [@b0550]).Fig. 2Biosynthesis of KMF.

2.2. Chemical synthesis {#s0020}
-----------------------

Chemically, KMF is synthesized by complex reaction having many steps: (a) cross aldol condensation of 2,4,6-trimethoxyacetophenone (6) and 4-methoxybenzaldehyde (7) with KOH, (b) *ortho*-demethylation of 2,4,6,4′- tetramethoxychalcone (8) in the presence of AlCl~3~, (c) I~2~-mediated oxidative cyclization of 2-hydroxy-4,6,4′-trimethoxychalcone (9), (d) methylation of 5-hydroxy-7-methoxy-2-(4-methoxyphenyl)chromen-4-one by Me~2~SO~4~ (10), (e) oxidative hydroxylation of 5,7-dimethoxy-2-(4-methoxyphenyl)chromen-4-one (11) catalysed by DDO, (f) BBr~3~ controlled catalytic demethylation of 3-hydroxy-5,7-dimethoxy-2-(4-methoxyphenyl)chromen-4-one (12) ([@b0445]) ([Fig.3](#f0015){ref-type="fig"} A).Fig. 3Schematic representations of methods for chemical synthesis of KMF. (A) Synthesis from 2,4,6-trimethoxyacetophenone; (B) Synthesis from *ω*-benzoyloxyphloracetophenone.

Another convenient method for KMF synthesis involves the reaction of *ω*-benzoyloxyphloracetophenone (13), *p*-(acetyloxy)benzoic anhydride (14), sodium *p*-acetyloxybenzoate (15) in the presence of triethylamine at 160--165 °C for 8 h, followed by mechanical stirring and aqueous KOH treatment that results in the formation of desired product ([@b0305]) ([Fig.3](#f0015){ref-type="fig"}B).

3. Therapeutic effects of kaempferol {#s0025}
====================================

3.1. Cell cycle arrest and apoptosis by kaempferol {#s0030}
--------------------------------------------------

Recent *in vitro* and *in vivo* studies have shown the antiproliferative and proapoptotic activities of KMF against various types of cancers including breast ([@b0025], [@b0370], [@b0465]), ovarian ([@b0510]), lung ([@b0425]), pancreas ([@b0855]), esophagus ([@b0825]), stomach ([@b0700]), colon ([@b0120]), prostate ([@b0255]), bladder ([@b0150]), kidney ([@b0705]) and others. Most of these studies demonstrate that the mechanism of KMF is dependent on the inhibition of proliferation of various cancer cells either via cell cycle arrest or induction of apoptosis ([@b0425], [@b0465]). KMF-dependent inhibition of cancer proliferation is mediated through arrest of the different phases of cell cycle ([Fig. 4](#f0020){ref-type="fig"} ) and inhibition of cell cycle transition points including G0/G1 transition in esophagus squamous cell carcinoma ([@b0825]) or G2/M transition in HT-29 human colon cancer cells ([@b0120]). KMF additionally inhibits the expression of various cyclins like cyclin D1 and cyclin E in breast cancer cells ([@b0370]), cyclin B1 in gastric cancer cells and renal cell carcinoma ([@b0705], [@b0700]) cyclin D, cyclin E and cyclin A in colon cancer cells ([@b0120]) and cyclin-dependent kinases like CDK4 and CDK2 ([@b0120]). KMF treatment has also been known to up-regulate the CDK inhibitors including p21 and p27 ([Fig. 4](#f0020){ref-type="fig"}). Furthermore, results of these studies demonstrate that KMF-dependent arrest of G0/G1 or G2/M transition is possibly due to inhibition of epidermal growth factor receptor (EGFR) activity, hexokinase-2 expression ([@b0825]), inhibition of the activity of estrogen ([@b0370]) or uptake of glucose ([@b0025]). Of note, growth factors, hormones, glucose and hexokinases are positive regulators of cell cycle.Fig. 4This figure depicts the cell cycle inhibitory effect of KMF through the regulation of various proteins molecules. KMF inhibits or reduces the expression of cyclin D/cdk 4/6, cyclin E/cdk 4/6, and cyclin B/cdc2 at G~1~/S and G~2~/M cell cycle check points. It increases the expression of p27, a member of the Kip/Cip family of CKIs which exerts negative regulation of CDK activity at G1/S phase transition. Similarly KMF is also known to enhance the expression level of cyclin-dependent kinase inhibitor p21^WAF1/Cip1^ which promotes the cell cycle arrest in response to various stimuli.

A large body of evidence indicates that KMF induces cancer cells apoptosis by activating the apoptosis-related signaling pathways ([Fig. 5](#f0025){ref-type="fig"} ). [@b0810] have indicated mitochondria in human cervical cancer cells (Hela cells) and HEK293 cells (embryonic kidney cells) as the source of KMF-dependent activation of intrinsic apoptotic signaling ([@b0810]). Further, studies by [@b0330] have substantiated that KMF could cause apoptosis MCF-7 breast cancer cells with estrogen receptor (ER) by activating intrinsic apoptosis signaling pathway and by down-regulation of PLK1 expression ([@b0330]). Similarly, [@b0700] have shown that in gastric cancer cells KMF decreases the expression level of an anti-apoptotic protein Bcl~2~ on the mitochondrial membrane and concomitant induction of pro-apoptotic protein Bax release from mitochondria ([@b0700]). Very recently, by utilizing a number of cancer cell lines, including human breast carcinoma (MCF-7) cells, human stomach carcinoma (SGC-7901) cells, human cervical carcinoma (Hela) cells and human lung carcinoma (A549) cells Laio et al. have attested that mitochondrial dysfunction is the major reason of KMF-dependent apoptosis induction in these cancer cells ([@b0465]). However, a number of other independent studies claimed that TNF cognate apoptosis-inducing ligand (TRAIL) is related to KMF-dependent apoptosis in cancer cells. Of note, the proinflammatory cytokine TNF-α, and TRAIL are cognate to the activation of extrinsic apoptosis signaling pathway. For example, [@b0835], have shown that KMF-dependent apoptosis in colon cancer cell lines is mediated by inducing TRAIL ([@b0835]). Likewise, TRAIL-KMF, mediated apoptosis is the result of suppression of survivin in human glioma cells ([@b0680]). Besides, KMF may also affect and inhibit various pro-survival molecules, i.e. Akt, PI(3)K, ERK 1/2 in the downstream signaling pathways ([@b0370], [@b0425]). KMF also suppresses cancer metastasis in osteosarcoma cells ([@b0105]) and induces autophagy (programmed cell survival) in human hepatic cancer cells ([@b0300]). It has been shown that carcinoma cells activate AMP-activated protein kinase-dependent autophagy as the survival response to KMF-mediated energetic impairment ([@b0195]). In summary, KMF decreases the number of various cancer cells through a multiprong mechanisms that include the arrest of the cell cycle, activation of proapoptotic proteins, inhibition of antiapoptotic proteins and by attenuating the phosphorylation and activity of prosurvival proteins (e.g. Akt) and activation of programmed cell survival or autophagy.Fig. 5KMF activates the apoptosis of the tumour cell through both intrinsic and extrinsic pathways. KMF depolarizes the mitochondrial membrane which causes the release of apoptosis mediators (cyt-c) in the cytoplasm. KMF also facilitates the formation of the apoptosome in the cytoplasm to induce apoptosis via caspase 3. It negatively regulates the expression of anti-apoptotic proteins like Bcl2, whereas positively regulate pro-apoptotic protein Bax. The components of extrinsic pathways such as caspase 8 are activated by KMF treatment. Furthermore, the surviving protein has also been down-regulated by the KMF treatment.

3.2. Anti-angiogenesis effect of kaempferol {#s0035}
-------------------------------------------

Cancer cells exhibit high metabolic rate to fulfil their energy requirements that in turn is found to be associated with the neovascularization (angiogenesis). A number of studies have reported the involvement of a variety of transcriptional (ERK 1/2, Akt, and MAPK) and growth factors (VEGF and FGF) in the tumour microenvironment for the neovascularization ([@b0340], [@b0345], [@b0350], [@b0415], [@b0770]). These factors are being targeted as therapeutic approach for the cure of cancer in advanced stages ([Fig. 6](#f0030){ref-type="fig"} ). Treatment of Huh7 cell with KMF under hypoxic (low oxygen tension) condition inhibits the HIF-1α protein through the inactivation of p44/42 MAPK pathways which could be possible ways of cancer inhibition ([@b0555]). In a study conducted by [@b0515] using human ovarian cancer cells, they suggested that KMF can inhibit angiogenesis significantly by altering the VEGF expression through both HIF dependent and independent (ESRRA) pathways ([@b0515]). In context to their previous studies [@b0495], [@b0500], [@b0505] further proposed a novel angio-prevention mechanism of KMF via down-regulation of ERK-NFκB-cMyc-p21-VEGF signaling pathway ([@b0495], [@b0500], [@b0505]). In *in vitro* (HUVECs model) and *in vivo* studies (zebrafish model), [@b0460] demonstrated the anti-angiogenic effect of KMF via VEGF and FGF angiogenic promoters inactivation that are further known to interact with tyrosine kinase-associated angiogenic receptors. [Fig. 6](#f0030){ref-type="fig"} summarizes the various above discussed molecular targets of KMF in the inhibition of cancer angiogenesis and further research is required to explore the remaining details of its mechanisms of action.Fig. 6This figure summarized the KMF-mediated anti-angiogenic and anti-metastatic effects. HIF-1α which initiates neovascularization under hypoxic condition in tumour is found to be inhibited by the KMF. VEGF and its receptor VEGFR mediated activation of endothelia cells are also attenuated in the presence of KMF. Furthermore, KMF inhibits the Akt/mTOR/p07S6K, a well resolved signaling pathways in the neovascularization during the tumour progression. It also inhibits the STAT3 or its phosphorylation that have been required for the signaling cascades via HIF-1α activation. Inflammatory mediators like iNOS which activates the VEGF are noticed as down-regulated by KMF. Moreover KMF also inhibits the MMPs (MMP 2 & 9) via inhibition of MAPK/Akt pathways, both of these enzymes are important for the ECM remodelling during the cancer progression and facilitate the cancer metastasis.

3.3. Anti-metastasis effect of kaempferol {#s0040}
-----------------------------------------

Metastasis is considered as a hallmark of uncontrolled proliferation of the tumour cells at primary site followed by the invasion to the nearby tissue and invasion to the distant organs via bloodstream. The EMT proteins (Epithelial-Mesenchymal-Transitions), such as E-cadherin, vimentin, fibronectin, matrix metalloproteases (MMPs) are known to play a paramount role in the process of metastasis by trailing the cell-cell contacts ([@b0675], [@b0780], [@b0875]). Therefore, EMT proteins are considered as promising targets to combat tumour metastasis. The STAT3 is another most widely studied transcription factor associated with cancer metastasis and survival which has been found to be suppressed by KMF treatment in human prostate cancer cells (DU145) ([@b0430]). In a study by [@b0105], the anti-metastatic effect of KMF in human osteosarcoma cells (OS) was investigated by inhibiting the DNA binding activity of a transcription factor called activator protein (AP-1) which resulted in reduced expression of MMP-2 & 9 ([@b0105]). Moreover, the other associated molecules, including ERK 1/2 and p38 were also found to be down-regulated under KMF treatment ([Fig. 6](#f0030){ref-type="fig"}). Similarly, ERK 1/2-mediated down-regulation of MMPs has observed in KMF-treated human tongue squamous cancer cells (SCC4) ([@b0470]). In another study, KMF suppressed the transforming growth factor-β1 (TGF-β1) induced human non--small cell lung cancer (NSCLC, A549) transition from epithelial-to-mesenchymal (EMT) and migration by abolishing Akt1-mediated Smad3 phosphorylation ([@b0190]). Correspondingly, [@b0270] observed the modulation of EMT-cognate proteins, including E-cadherin and vimentin in KMF-treated non-minuscule lung cancer cells ([@b0270]).

3.4. Anti-inflammatory effect of kaempferol {#s0045}
-------------------------------------------

Inflammation is known to be adopted by the tissues against various endogenous and exogenous pathogens. However, chronic inflammation has been considered to be associated with the progression of various diseases, including cancer, arthritis, and neurodegeneration ([@b0740], [@b0745], [@b0755]). KMF has been proven to be a potent inhibitor of pro-inflammatory molecules such as inducible nitric oxide synthase (iNOS), cyclooxygenase (COX), intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) ([@b0390], [@b0395], [@b0480]). The anti-inflammatory mechanisms of KMF are mainly mediated ([Fig. 7](#f0035){ref-type="fig"} ) by the down-regulation of several transcription factors, such as NF-κB (nuclear factor kappa B) and STAT that have ability to stimulate the activation of inflammatory molecules ([@b0260]). [@b0215] examined the anti-inflammatory potential of KMF in the human hepatocyte-derived cell line and proved that KMF was able to reduce the expression of C-reactive protein (CRP), COX-2, and iNOS via alterations in NF-κB pathway. Osteopontin (OPN), a reactive oxygen species (ROS)-dependent cytokine, which engenders and activates the p38 MAPK and NF-κB signaling, has been found to be down-regulated in aldosterone-induced human umbilical vein endothelial cells (HUVECs) by KMF ([@b0480]). Comparably, KMF treatment in lipopolysaccharide (LPS)-induced macrophages revealed the consequential down-regulation of COX-2, iNOS and TNF-α (tumour necrosis factor-α) both at transcriptional and translational levels via inhibition of NF-κB and AP-1 transcription factor ([@b0375], [@b0385]). Moreover, the protein kinase cascade mechanisms governed by Src, Syk, IRAK1, and IRAK4 that are usually involved in the activation of NF-κB and AP-1 transcriptional factors can also be blocked by KMF. The docking studies have substantiated the homogeneous binding energies of KMF as that of MG-132 which is considered to be a potent NF-κB inhibitor ([@b0325]). Therefore, evidences are suggesting that KMF may have great potential as an anti-inflammatory drug and could be introduced for *in vivo* trial.Fig. 7This figure elaborates the anti-inflammatory activity of KMF. KMF prevents the proteasome degradation of IKβ which forms complex with NF-кβ and stops its translocation in the nucleus. It also directly prevents the translocation of the NF-кβ in the nucleus and its binding to the DNA which otherwise activates the expression of various inflammatory genes. KMF inhibits the phosphorylation of the STAT6 which results in the inhibition of its translocation to nucleus thereby suppressing the activation of various inflammatory genes.

3.5. Antioxidant properties of kaempferol {#s0050}
-----------------------------------------

Reactive Oxygen Species (ROS) generated by enzymatic reactions during metabolism are the major source of harmful oxidative stress ([@b0010], [@b0275]). Although human body has antioxidant enzymes as a defenses mechanism that constantly neutralizes the ROS, the excess concentrations of ROS become fatal and cause cellular dysfunction, oxygen toxicity, senescent, stroke, autoimmune diseases, cancer, Parkinson's disease, infection and arteriosclerosis ([@b0010], [@b0535]). Studies have been performed using various funtional foods with antioxidant agents that may be availed to dispense ROS ([@b0200], [@b0380]). These results showed that flavonols could be effective secondary metabolites against oxidative stress ([@b0835]). KMF directly scavenges peroxynitrite (reactive nitrogen species) and hydroxyl radicals at low concentration whereas at high concentrations it enhances the expression of antioxidant enzymes ([@b0080]). The proposed mechanisms of action of KMF as a potent antioxidant have been reported to be associated with its up-regulatory effect on antioxidant response elements (ARE)-mediated antioxidative enzymes ([Fig. 8](#f0040){ref-type="fig"} ), such as heme oxygenase, catalase and superoxide dismutases (SODs) under the control of Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) signaling pathways ([@b0660]). KMF can also be utilized in the inhibition of platelet aggregation and LDL (Low-Density Lipoprotein) oxidative susceptibility ([@b0400]). [@b0125] extracted and purified KMF from the roots of *Rhodiola sachalinensis* and anticipated its antioxidant potential ([@b0125]). Similarly, [@b0785] extracted KMF from the beans of *Cassia alata* to study its antioxidant properties. KMF has additionally been found to bulwark myocardial ischemia/reperfusion (I/R) injury in rats by incrementing the calibers of SOD and decrementing the activity of P-GSK-3β ([@b0870]). In a study, utilizing 1,2-dimethyl hydrazine induced male Wistar rats, [@b0580] investigated that KMF treatment not only lowered down the erythrocyte lysate and thiobarbituric acid reactive substances (TBARS) but additionally up-regulated the antioxidant enzymes, including catalase, SOD, and glutathione peroxidase (Gpx) levels ([@b0580]). Likewise, hepatoprotective effect of KMF glycosides has been investigated against carbon tetrachloride-induced liver injuries in mice by uplifting the oxidative stress scavenging potential ([@b0795], [@b0800]). In osteoblast-like MC3T3-E1 cells, KMF inverted the antimycin A (AMA)-induced toxicity by averting the disruption of mitochondrial membrane potential and accumulation of intracellular calcium ions and ROS via P(I)3K-Akt-CREB pathway ([@b0130]).Fig. 8Schematic representations of anti-oxidant mechanisms of action of KMF. KMF positively regulates the Nrf2 expression, a crucial molecules known for anti-oxidant function. Mechanistically, KMF dissociates the Nrf2 from its repressor Keap1, prevent its degradation and facilitates its translocation to nucleus. KMF also stabilize the mitochondrial membrane potential and helps to reduce the ROS release in the cytoplasm.

3.6. Synergistic and other therapeutic effects of kaempferol {#s0055}
------------------------------------------------------------

Data about phytochemicals have proved that the synergistic properties of different flavonoids may not only be utilized to enhance the potential of chemotherapeutic drugs, but also to reduce the ineluctable side effects ([@b0420]; [@b0760], [@b0775]). In this scenario, KMF could act as a promising molecule to boost the therapeutic potential of the chemotherapy by refining the pharmacokinetics as well as by subsisting side effects of the therapy. A coalescence of quercetin, kaempferol and naringenin was found to be significantly more efficacious antiproliferative agent against mouse liver cancer cells Hepa-1c1c7 and human prostate cancer cells LNCaP ([@b0085]). In a study utilizing male SD rat models, [@b0815] observed that KMF improves the pharmacokinetics of nifedipine by reducing the drug metabolic processes ([@b0815]). Similarly, the pharmacokinetics of tamoxifen has also been found to be altered by KMF via inhibition of drug metabolizing enzymes, including CYP3A ([@b0605]). Besides inhibiting the activity of phase I CYPs enzymes, KMF additionally works as an inhibitor of multidrug resistance protein 1 (MDR1) or P-glycoproteins when co-administrated with etoposide and quercetin in rats and in human leukemic cells K562/A, respectively ([@b0450], [@b0820]). The neuroprotective effects of quercetin, KMF and biapigenin have been investigated against kainate and *N*-methyl-*D*-aspartate-induced neuronal cell death by [@b0685]. Utilizing ovarian cancer cell lines, Luo et al. investigated that KMF intensified the apoptotic effect of cisplatin by significantly down-regulating c-myc gene expression ([@b0490]). Thus, drug combinations could co-act and potentiate the control of intricate biological disorders. Besides governing these promising pharmacological effects, KMF has additionally been known to promote other organ protective effects as summarized in [Table 2](#t0010){ref-type="table"} .Table 2Summary of a variety of therapeutic effects of kaempferol.S. no.PropertyMechanismModelDoseReferences1Cardio-protectionIncrease SOD, P-GSK-3*β*, GSH/GSSG ratio, improve the recovery of LVDP, *dp*/*dt*max, and decrease cleaved caspase-3, cyt-C, CK, LDH, MDA, TNF-*α*Sprague-Dawley rat15 mmol/L[@b0870]Decrease TNF-*α*, IL-6, and NF-κβ, inhibit JNK and p38 protein, reduce expression of Bax and Caspase-3, increase Bcl-2 and activate ERK1/ERK2, prosurvival kinaseWistar rat20 mg/kg[@b0335]Activate BMP signaling pathway, induces miR-21 expression, downregulates DOCK4, 5, and 7 and antagonizes the PDGF-mediated pro-migratory effectVSMC cells50 μM[@b0385]Inhibit intrinsic and extrinsic pathways of apoptosis, and regulate SIRT1 expressionRat15 mM[@b0250]Inhibit CaMKII oxidizationMice15 mM[@b0545]Decrease TNF-α, IL-1β, MDA, E-sel, ICAM-1, VCAM-1 and MCP-1, and increase serum SODMale New Zealand white rabbit150 mg/kg and 30 mg/kg[@b0390], [@b0395]2Pulmonary and Asthma-protectionInhibit IRE1α- TRAF2-JNK activationBALB/c mice10 mg/kg[@b0695]Modulate Syk-PLC, and PKC-ERK-cPLA2-COX2 signaling in antigen-exposed mast cellsRat20 mg/kg[@b0145]Modulate Tyk2-STAT1/3 signaling and increase SODBEAS-2B cells and BALB/c mice⩽20  μM[@b0245]Inhibit alveolar wall thickness, alveolar hemorrhage and leukocytes infiltration, reduced MPO activity, inactivate MAPKs, and NF-kβ signaling pathwaysMale BALB/c mice100 mg/kg[@b0115]3Diabetic-protectionModulate AMPK activity, Glut4 expression, and improve islet *β*-cell massMice0.05%[@b0265]Ameliorate hyperglycemia by acting as partial agonists of PPARγ3T3-L1 preadipocytes10 μM[@b0845]Increase the activity of Sp1 through stimulation of Sp1 phosphorylation by ERK1/2 and subsequent induction of LDLR expression and activityHepG2 cells100 μM[@b0590]Inhibit the phosphorylation of insulin IRS-1, Ikβ kinase α, and Ikβ kinase βRat50 or 150 mg/kg[@b0520]Decrease activity of total ATPases, Na(+)/K(+)-ATPase, Ca(2+)-ATPase, and Mg(2+)-ATPase in erythrocytes and tissuesWistar rat100 mg/kg BW[@b0015]Inhibit α-glucosidase--1.16 ± 0.04 × 10(-5) mol L^-1^[@b0600]4Osteo-protectionInhibit bone marrow adipogenesisSprague--Dawley rat1 mg/kg[@b0635]Downregulate ER, and activate ERKMG-63 human osteoblasts50 mM[@b0135]Stimulate Krt-14 proteinOsteoblast cells5 μM[@b0360]Enhance the expression of chondrogenic marker genes, such as collagen type I, collagen type X, OCN, Runx 2, Sox 9, induced ERK, and increase expression of BMP-2ATDC5 cells5 μM[@b0565]5Neuro-protectionInhibit STAT 3, NF-kβ activation, interleukin 1β, intercellular adhesion molecule 1, MMP 9, iNOS, myeloperoxidase, and TNF-αMale Sprague-Dawley rat10.0 mg/kg and 7.5 mg/kg[@b0485]Inhibit MCP-1 productionMacrophage cell line J.774.230 μM[@b0315]Autophagic enhancement through LC3-II increaseRat30 μM[@b0240]Inhibit expression of OX-42, glial fibrillary acidic protein, phosphorylated STAT3, NF-κβ p65, the nuclear content of NF-κβ p65, inhibit expression of TNF-α, IL-1β, intercellular adhesion molecule 1, MMP 9, iNOS, and myeloperoxidaseSprague-Dawley rats--[@b0840]Improve motor coordination, raise striatal dopamine, increase SOD and GSH-PX activity, and reduce content of MDAMice--[@b0455]Down-regulate TLR4, NF-kβ, p38 MAPK, JNK and AKTMicroglial BV2 cells10--100 mM[@b0595]6Anti-depressantModulate POMC mRNA or plasma β-endorphinMale ICR mice, Male albino mice, and Wistar rat500 μl/25 g, 100 and 200 mg/kg in mice and 50 mg/kg in rat[@b0710], [@b0290]7Hepato-protectionInhibit ENRDRat hepatocytes0.1, 1, 10 μM/L[@b0860], [@b0865]Activate LXR-β and suppresses SREBP-1Mice150 mg/day/kg[@b0285]Attenuate the activity and expression of CYP2E1Mice13.23 μM/mL[@b0795], [@b0800]Decrease expressions of TGF-β1 and Smad 2/3, and increasing the expression of Smad 7BALB/c5, 10, 15, 20 mg/kg[@b0070]8Arthritis-protectionInhibit RANKL-mediated phosphorylation of ERK 1/2, p38, JNK MAP kinases, and expressions of c-Fos and NFATc1Mice100 μM[@b0440]Inhibit expression of MMP-1, MMP-3, COX-2, PGE2, phosphorylation of ERK-1/2, p38, JNK, and activation of NF-κβRASF cells100 μM[@b0830]9UV-protectionReduced CREB, c-Fos, histone H 3, and inhibit RSK2 and MSK1Human squamous cell carcinoma2.5 mg[@b0355]Suppresses COX-2 expression by blocking Src kinase activityJB6 P + mouse epidermal cells20 or 40 μM[@b0435]10Ovary-protectionInduce expression of PR regulated transcriptional targets (Hand2 and Areg) without PR degradationRat20 μM[@b0725]11ImmunosuppressantIncrease CD4 + FoxP3 + Tregs, suppress DC maturation and their IL-6 expressionMice0.1 mg[@b0850]12Anti-parasiticEntamoeba histolytica trophozoites, through deregulation of cytoskeleton-related protein--27.7 μM[@b0060]Chloroquine-resistant *P. falciparumP. falciparum* strain, K-1106 μM[@b0530]13Anti-viral effectInactivate virus by binding with JEV fsRNAVirus-infected BHK21 cells25 mM[@b0720]Anti-HIV-1 reverse transcriptasePBMCs100, 50, 25 and 10 μg/ml[@b0040]Coronavirus by targeting 3a channelXenopus oocyte20 μM[@b0665]Enterovirus 71 (EV71) by regulating IRES associated *trans*-acting factorsEV71 isolate35 μM[@b0735]14Anti-fungalReversion of resistant *C. albicans* by suppression of CDR1, CDR2, and MDR1*C. albicans* z2003128--256 μg/mL[@b0670][^3]

4. Absorption, metabolism and bioavailability of kaempferol {#s0060}
===========================================================

Although countless physiologically important functions of KMF have been described, poor bioavailability restricts its further clinical applications.

Flavonols are naturally dynamic polyphenolic compounds that are found in plants and plant-inferred nourishments of human diet. Their absorption as well as bioavailability in the blood is found to influence their ability to impact the cellular health. After intake, flavonoids undergo to metabolic processes as results of which they are enzymatically conjugated with sulphate, methyl or glycuronyl moieties.

Different methodologies, including estimation of dietary intake, determination of plasma or urinary level, have been used to study the absorption and bioavailability potential of flavonoids. In the USA and Netherlands, KMF gives an important contribution to the daily consumption of flavonoids (25--33%), with a mean intake of 6--10 mg/day ([@b0280], [@b0655]). Though, studies have been done concerning the assimilation of other flavonoids, like quercetin, the data on the bioavailability of KMF has still remained to elucidate. [@b0175], conducted a 7-days study by utilizing tea and onions-based diet in a group of volunteers to quantify the concentrations of KMF in plasma and urine ([@b0175]). Their results revealed that KMF was excreted in about 2.5% of its consumed quantity which was higher than for quercetin (0.5%) after 4 h of dose ingestion. Similarly, using healthy humans as subject models, [@b0180] have also reported the similar concentration (0.05 mM) of KMF in plasma after 4 h of intake of endive-based diet, containing up to 246 mg of KMF per kg ([@b0180]). In another study, researchers observed the KMF excrete about 0.9% of the total consumed flavonoids from broccoli ([@b0575]). Furthermore, the absorption rate of KMF from small intestine mainly depends on the microbial hydrolysis of β-glucuronide before aglycone uptake. [@b0645], reported that variation in the gut microflora population alters the absorption rate of KMF by modulating the process of hydrolysis of conjugates and alterations in aglycone ring ([@b0645]). Chromatographic studies revealed the presence of early absorption peak preferentially due to the absorption of kaempferol-3-glucoside. [@b0560], investigated that kaempferol-3-glucoside is the most preferred substrate for lactase-phlorizin hydrolase, as compared to kaempferol-3-(6-malonyl)-glucoside and kaempferol-3-glucuronide ([@b0560]). Being hydrophilic in nature, kaempferol-3-glucuronide is found to be absorbed directly from the small intestine. KMF glucosides are preferentially absorbed via mechanisms of active transport and deglycosylation processes as reported for quercetin absorption ([@b0160], [@b0155], [@b0230], [@b0560]). Hydroxylation is a phase I cytochrome P450 dependent enzymatic activity that is known to be involved in the metabolism of KMF. In a study, [@b0570], investigated the hydroxylation capability of microsomes toward flavonols and flavones ([@b0570]). Like quercetin, KMF may also be subjected to basic phase II metabolic conjugation in accumulation with glucuronide or sulphate ([@b0165]). It is essential to identify KMF metabolites to know the various circulating forms of this moiety. [@b0180], has observed the conjugated form of KMF metabolite i.e. kaempferol-3-glucuronide (55--80%) in the circulating plasma ([@b0180]). Another form of metabolite subsists as kaempferol-7-sulphate which could be due to the action of human hepatocytes ([@b0165]). These evidences have suggested the lesser bioavailability of KMF in the bloodstream, which needs to be improved with the aim to utilize the full therapeutic potential of KMF. Using *G. biloba* extract-phospholipid complexes (GBP) of KMF, [@b0110], have shown the increase in oral bioavailability of flavonoids including quercetin and KMF in a rat model ([@b0110]). Similarly, [@b0795], [@b0800], investigated that phospholipid complex (TFH-PC) of KMF may not only increase the bioavailability (172%) but also increase the solubility (22.0 folds) in comparison to total intake of flavonoids ([@b0795], [@b0800]). Another approach to improve the bioavailability of the therapeutically active flavonols is to explore the effect of the supplemented food matrix ingredients. So far, very limited data are reported about the effect of food ingredients on absorption and bioavailability of KMF. It has been found that the total absorption and bioavailability of flavonoids are associated with the composition of carbohydrate based food matrix. [@b0640], demonstrated that the maltitol and sucrose were found to increase and decrease the absorption of flavonoids by altering the activity of catechol-O-methyltransferase ([@b0640]). Also, the methylation of flavonoids, such as genistein and KMF, appeared to modulate the metabolism as well as transportation of these wonderful molecules. [@b0095], indicated that the methylation of KMF not only enhances its transporting ability but also increases its hydrophobicity which further assists in the absorption, bioavailability, and binding affinity to both HSA (human serum albumin) and ovalbumin ([@b0095]). Furthermore, route of administration and nanotechnology-mediated implementations in the drug delivery may also ameliorate the bioavailability of KMF. In [@b0030] reported that the half-life of KMF was 3--4 h and 1--2 h, respectively, after intravenous (10 and 25 mg/kg) and oral (100 and 250 mg/kg) dosages of KMF in male SD (Sprague-Dawley) rats ([@b0030]). In a study, [@b0495], [@b0500], [@b0505], observed that encapsulated poly (ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide) (PEO-PPO-PEO) and poly(DL-lactic acid-co-glycolic acid) drug dosages were found to be more efficacious than KMF alone ([@b0495], [@b0500], [@b0505]). Similarly, nano-suspension of KMF was found to improve its bioavailability as well as solubility by increasing the Cmax and Area under the curve (AUC~0-∞~) value ([@b0615]). Therefore, the data confirmed the significance of bioavailability and solubility of flavonoids to exert their bioactivity and indicated that improving these important pharmacokinetic parameters may probably further enhance the biological efficacy and potential physiological capacity of KMF.

5. Epidemiological findings of studies with kaempferol-rich foods {#s0065}
=================================================================

Epidemiological studies about association between kaempferol-rich foods intake and decrease in risk of certain types of cancer have shown the variable results depending on several factors, including population type, sample size, food composition, databases used, and other concurrent lifestyle determinants.

No association between consumption of KMF and total invasive cancer risk was found among middle-aged and older women in the Women's Health Study ([@b0790]). However, among 66,940 women included in the Nurses\' Health Study, Gates et al. observed a significant (40%) reduction in ovarian cancer incidence for the highest versus the lowest quintile of KMF intake ([@b0220]). On the other hand, a large-scale case-control study showed non-significant (21%) reduction in the incidence of ovarian cancer among women who were at highest quintile of KMF intake ([@b0225]). Similarly, a non-significant (27%) decrease in ovarian cancer risk was noted to be associated with a high KMF intake in a rather small case-control study (124 ovarian cancer cases and 696 population-based controls) conducted in the western New York ([@b0525]).

In addition, there was no evidence showing a relationship between KMF intake and breast cancer risk described in the Nurses Health Study II ([@b0005]), whereas a low consumption of KMF was significantly associated with decreased risk of estrogen receptor (ER) negative-neoplasias compared to ER-positive tumour among premenopausal women ([@b0730]). An inverse association of KMF intake with advanced stage (stage III/IV or stage IV, but not non-advanced) prostate cancer in the Netherlands Cohort Study was also described ([@b0235]). Although there was no remarkable relationships between high KMF intake and colorectal cancer risk among women from the Nurses' Health Study and men from the Health Professionals Follow-Up Study ([@b0475]), a statistically significant reduction in the risk of advanced adenoma recurrence was observed in Polyp Prevention Trial ([@b0050]). Furthermore, consumption of higher dose of KMF was found to be protective against gastric cancer in a case-control study conducted in the Spain ([@b0210]). KMF intake was also significantly associated with decreased risk of pancreatic cancer among current smokers (but not among never or former smokers) in the large Multiethnic Cohort Study with participants from Hawaii and California ([@b0585]) and among male smokers who were not consuming supplements of vitamin E or β-carotene in the α-Tocopherol, β-Carotene Cancer Prevention Study ([@b0055]). Moreover, high intakes of KMF were inversely associated with the development of lung tumour in a case-control study carried out in Los Angeles County, manifesting still only among tobacco smokers and not among non-smokers ([@b0140]). The data of a case-control study of lung cancer in women in Spain exhibited a non-significant association for the highest vs. lowest tertile intake of KMF ([@b0205]).

Consequently, in the above-presented findings, consuming KMF rich diet may be related to lower cancer risk which could be feasible in specific tumour types and in certain populations. More epidemiological studies with larger cohorts are required to further investigate the potential role of kaempferol-rich foodstuffs in prevention of chronic diseases, such as cancer.

6. Conclusion and future perspectives {#s0070}
=====================================

Functional foods have always been known to upgrade health benefits due to their broad spectrum of biological functions and interactions. Evidences have suggested the salutary effects of dietary KMF in plummeting the peril of lethal diseases, such as cancer. Current chemotherapeutic agents are known to pose serious health risks which could be solved by utilizing natural bioactive metabolites like KMF. However, the scientific community should always endeavour to ameliorate the potency of such wondrous molecules. As the structure of KMF revealed the availability of electron donor atoms, such as oxygen which can make the co-ordinate bond with metal atoms and resulting metal complexes of KMF may further boost its biological activity ([@b0340], [@b0345], [@b0765]). Computational implements like QSAR models can be acclimated to explore the unknown molecular interactions of KMF with recognized cellular receptors ([@b0065]). Synergistic amalgamations with other promising natural bioactive molecules could also be visually perceived as another prospective of future study to enhance the therapeutic potential of KMF ([@b0750]). Moreover, the role of KMF in modulating the expression and activity of drug metabolizing enzymes, such as CYPs could also avail the scientific communities to come forward to design novel strategies with subsisting chemotherapeutic agents ([@b0045], [@b0295], [@b0860], [@b0865]). Such approaches might be auxiliary in reducing the KMF-associated toxic ([@b0090], [@b0690]) effects by lowering the requisite of active dosages. Furthermore, novel derivatives of KMF could additionally be an option to ameliorate the potency as well as dose-associated toxicity of this molecule. Rho and his colleagues have designed KMF predicated rhamnosides and purposed them as a paramount moiety in the obviation of inflammatory disorders ([@b0630]). Lower potency of a drug has also been found to be associated with its poor solubility and low bioavailability that can further be amended by utilizing the modern nanotechnology implements ([@b0410], [@b0610]). [@b0495], [@b0500], [@b0505], have designed a novel nano-formulation for KMF utilizing Poly DL-lactic acid-co-glycolic acid, nanoparticles with amended bioavailability and cytotoxic effect against ovarian cancer ([@b0495], [@b0500], [@b0505]). Moreover, the acerbic and astringent taste of most of the flavonoids could additionally be overcome by utilizing the nanotechnology mediated encapsulation processes which may further enhance their applicability on the more astronomically immense scale in aliment items ([@b9000]). Thus, KMF could prove to be a promising therapeutic agent and is certainly worth of further molecular studies.
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[^1]: Sources adopted from [@b0550] and [@b0310].

[^2]: Further details have been cited in [@b0080].

[^3]: Foot Note - SOD (Superoxide dismutase), P-GSK-3*β* (Glycogen Synthase Kinase 3), LVDP (Left Ventricular Developed Pressure), cyt-C (cytochrome-c), CK (Creatine kinase), LDH (Lactate dehydrogenase), MDA (Malondialdehyde), TNF-*α* (Tumour necrosis factor-*α*), IL-6 (Interleukin 6), NF-*κ*β (nuclear factor kappa-light-chain-enhancer of activated B cells), JNK (c-Jun N-terminal kinases), Bax (Bcl-2-associated X protein), Bcl-2 (B-cell lymphoma 2), Dock4, (Dedicator of cytokinesis 4), SIRT 1 (Sirtuin 1), PDGF (Platelet-derived growth factor), CaM kinase II (Ca2+/calmodulin-dependent protein kinase II), IL1β (Interleukin 1 beta), ICAM-1 (Intercellular Adhesion Molecule 1), VCAM-1 (Vascular cell adhesion protein 1), MCP-1 (Monocyte Chemoattractant Protein-1), COX-2 (Cyclooxygenase-2), STAT1/3 (Signal transducer and activator of transcription 3), MPO (myeloperoxidase), MAPK (Mitogen-activated protein kinase), AMPK (AMP-activated protein kinase), PPARγ (Peroxisome proliferator-activated receptor), Sp1 (specificity protein 1), ERK (Extracellular signal--regulated kinases), Krt-14 (Keratin 14), BMP2(Bone morphogenetic protein 2), MMP-9 (Matrix metallopeptidase 9), iNOS (Inducible nitric oxide synthase), GSH-PX (Glutathione peroxidase), TLR4 (Toll-like receptor 4), AKT (Protein kinase B), LXR-β (Liver X receptor-β), SREBP-1 (Sterol regulatory element-binding proteins), CYP2E1 (Cytochrome P450 2E1), TGF-β1 (Transforming growth factor beta 1), NFATc1 (nuclear factor of activated T-cells 1), CREB (cAMP response element-binding protein).
